Source comparison
Mechanism of Action: GHRH Analog vs Ghrelin Mimetic
CJC-1295 functions as a modified version of naturally occurring growth hormone-releasing hormone, extended with a Drug Affinity Complex that binds to serum albumin and prolongs circulating half-life from minutes to days. When administered, it stimulates GHRH r
This comparison does not assign a generated winner or score.
- CJC-1295 functions as a modified version of naturally occurring growth hormone-releasing hormone, extended with a Drug Affinity Complex that binds to serum albumin and prolongs circulating half-life from minutes to days. When administered, it stimulates GHRH receptors on pituitary somatotrophs. The cells responsible for synthesising and secreting GH. Triggering release in response to the body's natural pulsatile signals. Because it amplifies existing GH pulses rather than creating new continuous signals, CJC-1295 maintains the physiological rhythm critical for downstream anabolic signaling without overriding negative feedback from somatostatin, the hormone that suppresses GH release between pulses. Research published in the Journal of Clinical Endocrinology & Metabolism found that GHRH analogs preserved pulsatile secretion patterns in clinical models, avoiding the blunted response seen with sustained GH elevation.
- MK-677 operates through a completely different pathway. It's a selective agonist of the ghrelin receptor (growth hormone secretagogue receptor, or GHS-R1a), located in both the hypothalamus and the pituitary. Ghrelin is the endogenous "hunger hormone" that also stimulates GH release. MK-677 mimics ghrelin's GH-stimulating effects without triggering the same appetite signaling in all research models. Because it bypasses GHRH entirely, MK-677 doesn't depend on GHRH receptor availability or sensitivity, and it elevates both GH and IGF-1 simultaneously through direct pituitary action and hepatic IGF-1 synthesis. The trade-off: sustained receptor activation can lead to gradual desensitisation in some long-duration studies, reducing the magnitude of GH elevation after 8–12 weeks of continuous dosing. This is why some protocols cycle MK-677 or pair it with intermittent dosing schedules.